Cytosorbents Corporation (NASDAQ:CTSO) came out with its quarterly results last week, and we wanted to see how the business is performing and what industry forecasts think of the company following this report. Revenues were in line with expectations, at US$9.6m, while statutory losses ballooned to US$0.07 per share. This is an important time for investors, as they can track a company's performance in its report, look at what expert is forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analyst is expecting for next year.

After the latest results, the sole analyst covering Cytosorbents are now predicting revenues of US$39.6m in 2026. If met, this would reflect a credible 6.4% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 36% to US$0.18. Before this latest report, the consensus had been expecting revenues of US$38.3m and US$0.18 per share in losses. Overall it looks as though the analyst were a bit mixed on the latest consensus updates. Although there was a nice uplift to revenue, the consensus also made a moderate increase in its losses per share forecasts.

It will come as no surprise that expanding losses caused the consensus price target to fall 42% to US$2.88with the analyst implicitly ranking ongoing losses as a greater concern than growing revenues.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. One thing stands out from these estimates, which is that Cytosorbents is forecast to grow faster in the future than it has in the past, with revenues expected to display 13% annualised growth until the end of 2026. If achieved, this would be a much better result than the 3.8% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 7.6% annually. So it looks like Cytosorbents is expected to grow faster than its competitors, at least for a while.

The Bottom Line

The most important thing to take away is that the analyst increased their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. The consensus price target fell measurably, with the analyst seemingly not reassured by the latest results, leading to a lower estimate of Cytosorbents' future valuation.

With that in mind, we wouldn't be too quick to come to a conclusion on Cytosorbents. Long-term earnings power is much more important than next year's profits. At least one analyst has provided forecasts out to 2028, which can be seen for free on our platform here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.